## REFERENCES

Enclosures and References\* (Items marked with an asterisk are references only and are not enclosed)

5.Incidence and Prevalence Database. Accessed from www.tdrdata.com/IncidenceAndPrevalenceDatabase.htm.

6. <u>http://www.cdc.gov/ncbddd/folicacid/fact/folicfaqs.htm</u>,Updated March 2002

8\*. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington, DC: National Academy Press, 1998. Accessible at http://books.nap.edu/books/0309065542/html/indes.html (National Academy Press Webpage).

**9**. Bailey LB. New standard for dietary folate intake in pregnant women. Am J Clin Nutr 2000;71(5 Suppl):1304S-7S.

10. Gregory JF et al. Kinetic model of folate metabolism in nonpregnant women consuming folic acid: isotopic labeling of urinary folate and the catabolite para-acetamidobenzoylglutamate indicates slow, intake-dependent, turnover of folate pools. J Nutr 1998;128:1896-1906.

11. Gregory et al. Kinetics of folate turnover in pregnant women (second trimester) and nonpregnant controls during folic acid supplementation: stable-isotopic labeling of plasma folate, urinary folate and folate catabolites shows subtle effects of pregnancy on turnover of folate pools. J Nutr 2001;131:1928-1937.

**12**. Heseker H et al. Effect of long-term supplementation of folate on folate status in plasma and erythrocytes. J Nutr Sci Vitaminol 1987;33:163-168.

**13**. Brouwer IA et al. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am J Clin Nutr 1999;69:99-104.

14. Wald DS et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001;161:695-700.

**15**. Ward M et al. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. Q J Med 1997;90:519-524.

16\*. Burnham TH et al (eds). Drug Facts and Comparisons® 2002. St. Louis, MO: Folic Facts and Comparisons®.

**17**. Based on a telephonic communication with the FDA – contact info obtained from http://www.cfsan.fda.gov/~dms/ds-rept.html.

18\*. Miller, D.R and K.C. Hayes. 1982. Vitamin excess and toxicity. Pp 81-133 in J.N. Hathcock, ed. Nutritional Toxicology, Vol.1. Academic Press, New York.

<sup>1.</sup> Hobbins, J.C. Diagnosis and management of neural-tube defects today. New England Journal of Medicine 324. 1991: 690-691.

<sup>2.</sup> http://www.cdc.gov/ncbddd/folicacid/folicfaqs.htm.

**<sup>3</sup>**. Botto., L.D., et al. Medical progress: neural-tube defects. New England Journal of Medicine 341. 1999: 1509-1519.

<sup>4.</sup> Neural Tube Defects. ACOG Practice Bulletin Number 44, July 2003. Obstet Gynecol 2003;102(1):203-213.

**<sup>7</sup>**\*. Wagner, C. Biochemical role of folate in cellular metabolism. In Folate in Health and Disease. Marcel Dekker, New York, NY, USA 1995, L.B. Bailey, Ed: 23-42.